Maassoumeh Akhlaghi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maassoumeh Akhlaghi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ahmadreza Jamshidi
Rheumatology Research center, Tehran University of medical sciences, Tehran, Iran
2 shared publications - Alireza Mirzamohamadi
Center for Orthopedic Trans‐Disciplinary Applied Research, Shariati Hospital Tehran University of Medical Sciences Tehran Iran
2 shared publications - Cornelia M. Weyand
Department of Medicine, Mayo Clinic Alix School of Medicine, Rochester, USA
1 shared publication - Elham Madreseh
Rheumatology Research center, Tehran University of medical sciences, Tehran, Iran
1 shared publication - Farhad Shahram
Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 3439123900, Iran
1 shared publication - Fereydoun Davatchi
Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 3439123900, Iran
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (12)
Drooling as a Red Flag: Insights From a Case Series in Severe Dermatomyositis With Literature Review
Dermatomyositis (DM) is a rare idiopathic inflammatory disease characterized by progressive proximal muscle weakness and distinctive dermatologic manifestations. Although dysphagia is a recognized complication of oropharyngeal muscle involvement, drooling (sialorrhea) is infrequently described and may be a marker of severe disease. This case series reports three adult patients with severe DM who presented with drooling, highlighting diagnostic challenges and therapeutic dilemmas in the management of refractory disease. All patients in the present study exhibited severe DM with prominent dysphagia, leading to drooling. Despite intensive immunosuppressive therapy, including high‐dose corticosteroids, immunosuppressants, intravenous immunoglobulin, and Rituximab, the outcome was disappointing, highlighting the refractory nature of the disease. The patients experienced readmissions following the worsening of dysphagia and drooling, which eventually led to complications like aspiration pneumonia and sepsis and ultimately fatal outcomes. Anti‐Ro52 and Anti‐Nuclear Matrix Protein 2 (NXP2) antibodies correlated with a more severe disease course and poor prognosis. Although rare, drooling in DM may be a clinical marker of severe DM with extensive oropharyngeal involvement and an increased risk for life‐threatening complications. Early evaluation and initiation of intensive combination therapy could improve patient outcomes. Further research is needed to refine treatment protocols for this challenging manifestation of DM patients.
- 8 December 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (12)
Open AccessDrooling as a Red Flag: Insights From a Case Series in Severe Dermatomyositis With Literature Review
Dermatomyositis (DM) is a rare idiopathic inflammatory disease characterized by progressive proximal muscle weakness and distinctive dermatologic manifestations. Although dysphagia is a recognized complication of oropharyngeal muscle involvement, drooling (sialorrhea) is infrequently described and may be a marker of severe disease. This case series reports three adult patients with severe DM who presented with drooling, highlighting diagnostic challenges and therapeutic dilemmas in the management of refractory disease. All patients in the present study exhibited severe DM with prominent dysphagia, leading to drooling. Despite intensive immunosuppressive therapy, including high‐dose corticosteroids, immunosuppressants, intravenous immunoglobulin, and Rituximab, the outcome was disappointing, highlighting the refractory nature of the disease. The patients experienced readmissions following the worsening of dysphagia and drooling, which eventually led to complications like aspiration pneumonia and sepsis and ultimately fatal outcomes. Anti‐Ro52 and Anti‐Nuclear Matrix Protein 2 (NXP2) antibodies correlated with a more severe disease course and poor prognosis. Although rare, drooling in DM may be a clinical marker of severe DM with extensive oropharyngeal involvement and an increased risk for life‐threatening complications. Early evaluation and initiation of intensive combination therapy could improve patient outcomes. Further research is needed to refine treatment protocols for this challenging manifestation of DM patients.
- Open Access
- 19 June 2025
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 20 (3) , 253-262
Self-reported Adherence to Treatment and Disease Activity in Patients with Rheumatoid Arthritis from Iran; Based on RHEUMATRY-RA Registry: A Cross-sectional Study
Background: Poor medication adherence challenges efficacy and costs in achieving treatment goals for rheumatoid arthritis (RA). This study aimed to determine the prevalence of treatment adherence and its related factors in Iranian RA patients. Methods: This cross-sectional study included RA outpatients referred to the rheumatology clinic of Shariati Hospital between March 2017 and September 2018, with the diagnosis based on the American College of Rheumatology (2010 ACR/EULAR) criteria. Treatment adherence was evaluated using the standardized Persian version of the 8-item Morisky Medication Adherence Scale (MMAS-8). Demographic and clinical information was extracted through the Iranian RA registry system (RHEUMATRY-RA). Results: Of 275 participants (222(81%) female), 20(7%) patients had active RA. Medication adherence was low in 138(50%) of patients, moderate in 81(30%) and high in 56(20%). In patients with disease duration ≤ 10 years, medication adherence was significantly associated with sex and occupation. It was observed that older patients (adjusted odds ratio (aOR) (95% confidence interval (CI): 1.01(0.98, 1.03)) and women (aOR (95% CI): 1.64(0.60, 4.45)) had more adherence. Patients on glucocorticoids demonstrated higher (aOR (95% CI): 1.76(0.81, 3.84)) and on methotrexate lower (aOR (95% CI): 0.58(0.18, 1.86)) adherence. The odds of disease activity were 21% lower in people who had adhered to medication (aOR (95% CI): 0.79(0.29, 2.15)). Conclusion: Despite the inherent complexity of adherence behaviors, this study identified a high prevalence of poor medication adherence among RA patients. Patients with better adherence may have lower disease activity, underscoring its role in effective disease management.
- 19 June 2025
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 20 (3) , 253-262
Open AccessSelf-reported Adherence to Treatment and Disease Activity in Patients with Rheumatoid Arthritis from Iran; Based on RHEUMATRY-RA Registry: A Cross-sectional Study
Background: Poor medication adherence challenges efficacy and costs in achieving treatment goals for rheumatoid arthritis (RA). This study aimed to determine the prevalence of treatment adherence and its related factors in Iranian RA patients. Methods: This cross-sectional study included RA outpatients referred to the rheumatology clinic of Shariati Hospital between March 2017 and September 2018, with the diagnosis based on the American College of Rheumatology (2010 ACR/EULAR) criteria. Treatment adherence was evaluated using the standardized Persian version of the 8-item Morisky Medication Adherence Scale (MMAS-8). Demographic and clinical information was extracted through the Iranian RA registry system (RHEUMATRY-RA). Results: Of 275 participants (222(81%) female), 20(7%) patients had active RA. Medication adherence was low in 138(50%) of patients, moderate in 81(30%) and high in 56(20%). In patients with disease duration ≤ 10 years, medication adherence was significantly associated with sex and occupation. It was observed that older patients (adjusted odds ratio (aOR) (95% confidence interval (CI): 1.01(0.98, 1.03)) and women (aOR (95% CI): 1.64(0.60, 4.45)) had more adherence. Patients on glucocorticoids demonstrated higher (aOR (95% CI): 1.76(0.81, 3.84)) and on methotrexate lower (aOR (95% CI): 0.58(0.18, 1.86)) adherence. The odds of disease activity were 21% lower in people who had adhered to medication (aOR (95% CI): 0.79(0.29, 2.15)). Conclusion: Despite the inherent complexity of adherence behaviors, this study identified a high prevalence of poor medication adherence among RA patients. Patients with better adherence may have lower disease activity, underscoring its role in effective disease management.
- Open Access
- 15 October 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
Presentation of a case with fever, lymphadenopathy and thrombocytopenia: a case report
The three primary differential diagnoses for a patient with systemic and hematological involvements (fever, lymphadenopathy, and hepatosplenomegaly), skin rashes, and sore pharynx are infections, connective tissue diseases, and malignancies. In this case report, we discuss possible illusory similarities between these categories that can aid in the diagnostic workup of primary care physicians. Practical Implications. The clinical course of (Infections mononncleosis, MI) patients with and their histopathological data rarely differ; Therefore, early testing for IM caused by EBV is recommended. This article will help physicians face similar cases
- 15 October 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
Open AccessPresentation of a case with fever, lymphadenopathy and thrombocytopenia: a case report
The three primary differential diagnoses for a patient with systemic and hematological involvements (fever, lymphadenopathy, and hepatosplenomegaly), skin rashes, and sore pharynx are infections, connective tissue diseases, and malignancies. In this case report, we discuss possible illusory similarities between these categories that can aid in the diagnostic workup of primary care physicians. Practical Implications. The clinical course of (Infections mononncleosis, MI) patients with and their histopathological data rarely differ; Therefore, early testing for IM caused by EBV is recommended. This article will help physicians face similar cases
- Open Access
- 16 October 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (4) , 199-206
Geographical variations in ocular and extra-ocular manifestations in Behçet’s disease
Objective: Behçet’s disease (BD) is a rare vasculitis that results in multi-organ inflammatory disease. At-risk populations are most prevalent in the Middle East and East Asia. Clinical data on BD in Western countries, especially in the United States, are scarce. We have compared clinical patterning of BD vasculitis in two geographically defined patient cohorts in the Western United States and Iran. Methods: Comparative analysis of a retrospective cohort of 56 patients with BD evaluated at Stanford University Hospital between 2000 and 2016 and a cohort of 163 patients from the BD Registry at Tehran University of Medical Sciences. Clinical, demographic, laboratory, and treatment data were available. Comparisons were performed using descriptive statistics, Student’s t-test, and χ2-test. Results: The Stanford patients with BD were significantly younger at disease onset, had a higher proportion of females, and had longer disease duration than Iranian patients with BD. Genital ulcers, skin, joint, neurological, vascular, cardiopulmonary manifestations were all significantly more common in the Stanford cohort and 38% of Stanford patients had four or more organ systems involved compared with approximately 10% of Iranian patients. In contrast, Stanford patients had fewer ocular lesions (Stanford 21.4% vs. Iran 53.4% p<0.05), with the biggest difference seen for retinal vasculitis. Conclusion: Patients with BD from the Western US have a more severe disease course when compared to Iranian patients with BD, as demonstrated by earlier onset and a higher rate of multi-organ involvement. The high risk of Iranian patients with BD developing vasculitis of ocular structures suggests distinct pathomechanisms driving ocular versus extra-ocular BD. Cite this article as: Shahram F, Mæhlen MT, Akhlaghi M, Davatchi F, Liao YJ, Weyand CM. Geographical variations in ocular and extra-ocular manifestations in Behçet’s disease. Eur J Rheumatol 2019; 6(4): 199-206.
- 16 October 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (4) , 199-206
Open AccessGeographical variations in ocular and extra-ocular manifestations in Behçet’s disease
Objective: Behçet’s disease (BD) is a rare vasculitis that results in multi-organ inflammatory disease. At-risk populations are most prevalent in the Middle East and East Asia. Clinical data on BD in Western countries, especially in the United States, are scarce. We have compared clinical patterning of BD vasculitis in two geographically defined patient cohorts in the Western United States and Iran. Methods: Comparative analysis of a retrospective cohort of 56 patients with BD evaluated at Stanford University Hospital between 2000 and 2016 and a cohort of 163 patients from the BD Registry at Tehran University of Medical Sciences. Clinical, demographic, laboratory, and treatment data were available. Comparisons were performed using descriptive statistics, Student’s t-test, and χ2-test. Results: The Stanford patients with BD were significantly younger at disease onset, had a higher proportion of females, and had longer disease duration than Iranian patients with BD. Genital ulcers, skin, joint, neurological, vascular, cardiopulmonary manifestations were all significantly more common in the Stanford cohort and 38% of Stanford patients had four or more organ systems involved compared with approximately 10% of Iranian patients. In contrast, Stanford patients had fewer ocular lesions (Stanford 21.4% vs. Iran 53.4% p<0.05), with the biggest difference seen for retinal vasculitis. Conclusion: Patients with BD from the Western US have a more severe disease course when compared to Iranian patients with BD, as demonstrated by earlier onset and a higher rate of multi-organ involvement. The high risk of Iranian patients with BD developing vasculitis of ocular structures suggests distinct pathomechanisms driving ocular versus extra-ocular BD. Cite this article as: Shahram F, Mæhlen MT, Akhlaghi M, Davatchi F, Liao YJ, Weyand CM. Geographical variations in ocular and extra-ocular manifestations in Behçet’s disease. Eur J Rheumatol 2019; 6(4): 199-206.